Eton Pharmaceuticals (ETON) Total Non-Current Liabilities (2017 - 2026)

Eton Pharmaceuticals has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $65.3 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities fell 7.75% year-over-year to $65.3 million; the TTM figure through Jun 2026 stood at $65.3 million (down 7.75% YoY), while the FY2025 annual figure was $60.7 million, up 21.77% from the prior year.
• Total Non-Current Liabilities came in at $65.3 million for Q2 2026 at Eton Pharmaceuticals, up from $60.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $76.2 million in Q3 2025 to a low of $16.3 million in Q4 2023.
• Average Total Non-Current Liabilities over 4 years is $56.4 million, with a median of $60.7 million recorded in 2025.
• Year-over-year, Total Non-Current Liabilities soared 206.62% in 2024 and decreased 7.75% in 2026.
• Over 4 years, Total Non-Current Liabilities stood at $16.3 million in 2023, then soared by 206.62% to $49.9 million in 2024, then advanced by 21.77% to $60.7 million in 2025, then rose by 7.52% to $65.3 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $65.3 million in Q2 2026, $60.7 million in Q4 2025, and $76.2 million in Q3 2025.